Mount Sinai Fuster Heart Hospital: Topics in Cardiology

1. Explain the rationale for testing to assess underlying coronary disease based on current treatment paradigms and guidelines in order to optimize diagnostic accuracy and improve patient outcomes
2. Discuss the role of specific classes of hypoglycemic agents in decreasing cardiovascular and renal outcomes and be confident in starting optimal therapy and adjusting background therapy to optimize patient outcomes
3. Describe the multitude of percutaneous valvular interventions available to their patients and be better able to guide them towards the appropriate procedure to effect better patient outcomes

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Mitigation of Relevant Financial Relationships

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Michael J. Robbins, MD
Associate Professor of Medicine, Cardiology
Mount Sinai Fuster Heart
Rego Park, NY

Course Director, Faculty

Nothing to disclose

Deepak L Bhatt, MD, MPH, MBA, FACC, FAHA,FESC,MSCAI
Director of Mount Sinai Fuster Heart Hospital
Dr. Valentin Fuster Prof of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai, NY

Faculty

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol Myers Squibb|Stocks or stock options, excluding diversified mutual funds-Bristol Myers Squibb|Grant or research support-89 Bio|Grant or research support-Amgen|Grant or research support-Astrazeneca|Grant or research support-Bayer|Grant or research support-Boehringer Ingelheim Boehringer Ingelheim|Grant or research support-Boston Scientific|Grant or research support-Eli Lilly|Grant or research support-Janssen|Grant or research support-Novartis|Grant or research support-Novo Nordisk|Grant or research support-Pfizer Pharmaceuticals|Grant or research support-Sanofi Genzyme|Grant or research support-Afimmune|Grant or research support-Amarin|Grant or research support-Amgen|Grant or research support-Chiesi|Grant or research support-Faraday|Grant or research support-Fractyl|Grant or research support-Idorsia|Grant or research support-Lexicon|Grant or research support-Medtronic|Grant or research support-PhaseBio|Grant or research support-PLx Phama

jeffrey mechanick, MD
icahn sch of med at mount sinai
New York, NY

Faculty

Honoraria-Abbot Nutrition|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Aveta Life|Membership on Advisory Committees or Review Panels, Board Membership, etc.-L- Nutra (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Twin health

Samin K. Sharma, MD, MSCAI, FACC
Director, Cardiovascular Clinical Institute/Senior Vice President, Operations and Quality, Mount Sinai Fuster Heart Hospital
Director, Interventional Cardiology, Mount Sinai Health System/ President Mount Sinai Heart Network

Faculty

Nothing to disclose

Thursday, November 9, 2023